Freshfields advises Affimed on its strategic collaboration with Artiva Biotherapeutics for joint development and commercialization of a combination immuno-oncology therapy.
Affimed acted as the acquirer in this Strategic Collaboration transaction.
The acquisition targeted assets operating in the Healthcare sector.
The transaction was announced on 09 Nov 2022 with a reported value of 3000000000.0.
Generated by AI, original source from - Data is in progress
Artiva Biotherapeutics advisor
Firm name is in progress
Found it useful? Spread the word.
Freshfields advises Affimed on its strategic collaboration with Artiva Biotherapeutics for joint development and commercialization of a combination immuno-oncology therapy. | The Sponsor - The Sponsor
